These results indicate that the majority of inhibitor-resistant cancers retained the KRAS G12C allele, suggesting that an immunotherapy targeting the inhibitor-modified cysteine residue could be a generally feasible approach to combat acquired resistance to pharmacological inhibition. Here, KRAS is linked to cancer.